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ABSTRACT
CpG dinucleotides are mutational hotspots
associated with cancer and genetic diseases.
Thymine DNA glycosylase (TDG) plays an integral
role in CpG maintenance by excising mispaired
thymine and uracil in a CpG context and also partic-
ipates in transcriptional regulation via gene-specific
CpG demethylation and functional interactions
with the transcription machinery. Here, we report
that protein kinase C a (PKCa) interacts with TDG
and phosphorylates amino-terminal serine residues
adjacent to lysines acetylated by CREB-binding
protein (CBP) and p300 (CBP/p300). We establish
that acetylation and phosphorylation are mutually
exclusive, and their interplay dramatically alters
the DNA mispair-processing functions of TDG.
Remarkably, acetylation of the amino-terminal
region abrogates high-affinity DNA binding and
selectively prevents processing of G:T mispairs.
In contrast, phosphorylation does not markedly
alter DNA interactions, but may preserve G:T
processing in vivo by preventing CBP-mediated
acetylation. Mutational analysis suggests that
the acetyl-acceptor lysines are not directly involved
in contacting DNA, but may constitute a con-
formationally sensitive interface that modulates
DNA interactions. These findings reveal opposing
roles of CBP/p300 and PKCa in regulating the
DNA repair functions of TDG and suggest that the
interplay of these modifications in vivo may be
critically important in the maintenance of CpG
dinucleotides and epigenetic regulation.
INTRODUCTION
Cytosine methylation in vertebrates is an important
epigenetic mechanism regulating gene expression (1) that
also contributes to CpG dinucleotide instability by
promotingspontaneousbasedamageandincreasedsuscep-
tibility to endogenous and environmental mutagens (2).
Hydrolytic deamination of cytosine and 5-methylcytosine
respectively generates uracil (U) and thymine (T)
moieties mispaired with guanine (G) (3). If these G:T/
U mispairs remain unrepaired, they give rise to C to T
transition mutations associated with oncogenic transfor-
mation and genetic diseases (4). In fact, 25% of all
somatic mutations in the p53 tumor suppressor gene in
human tumors involve C to T transitions at CpG, and, in
some tumors, this ﬁgure rises to almost 50% (5).
Thymine DNA glycosylase (TDG) and methyl-CpG
binding domain protein 4 (MBD4) mediate excision of
mispaired thymine (G:T) and uracil (G:U) in the CpG
context (6–8) and also process various modiﬁed
pyrimidines (9). Excision of the aberrant base generates
a cytotoxic abasic site that is subsequently processed
by the coordinated action of other base-excision repair
(BER) enzymes, including apurinic/apyrimidinic endonu-
clease (APE) and DNA polymerase b (Polb) (10). MBD4
localizes predominantly to transcriptionally inactive
heterochromatin while TDG is mostly excluded from
these regions and associates with sequence speciﬁc tran-
scription factors and cofactors (11–15). These ﬁndings
suggest that TDG is targeted to transcriptionally active
regions of the genome and that BER may be coupled to
transcription. Interestingly, overexpression of TDG was
shown to reactivate a hormone-regulated transgene
silenced by CpG methylation, suggesting a role for TDG
in epigenetic regulation (16). Recent studies have
demonstrated that recruitment of TDG, in concert with
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the promoter regions of estrogen-responsive genes is
essential to establish cyclic methylation/demethylation
patterns in transcriptionally active chromatin (17).
TDG contains a highly conserved central glycosylase
domain ﬂanked by divergent amino- and carboxy-terminal
regions (18). The amino-terminal region of mammalian
TDG contains a hydrophilic lysine-rich region (residues
70–118) that is acetylated by CREB-binding protein
(CBP) and p300 (CBP/p300) while the carboxy-terminal
region is modiﬁed by covalent conjugation of small
ubiquitin-like modiﬁer (SUMO) protein (15,19). The
amino-terminal region is essential for nonspeciﬁc
DNA interactions as well as tight binding to abasic sites
and processing of G:T mispairs (18,20,21). The tight
association of TDG to the abasic site following base
excision prevents enzyme turnover, thereby limiting
mispair-processing eﬃciency (21). TDG contains two
separate SUMO-binding motifs located in the amino-
and carboxy-terminal regions that mediate noncovalent
binding to SUMO, which is required for translocation to
PML oncogenic domains (20).
CBP/p300 and TDG form ternary complexes with DNA
in vitro that retain the ability to mediate base excision and
histone acetylation, suggesting that the recruitment of
CBP/p300 in vivo may promote chromatin remodelling
at the site of repair (15). Furthermore, TDG potentiates
CBP-dependent transcription by means of intrinsic
SUMO-binding activity (20). Covalent SUMO conjuga-
tion to a carboxy-terminal lysine residue eﬀectively abro-
gates DNA binding and association with CBP, while
acetylation of the amino-terminal region may regulate
interactions with accessory factors (15,20,21). The
reported eﬀects of CBP/p300-mediated acetylation on
the activities of BER enzymes (TDG, Polb and ﬂap
endonuclease 1) (15,22,23) suggest an important role for
CBP/p300 in coordinating BER.
In light of the critical role of the amino-terminus in G:T
processing, we have undertaken to identify additional
covalent modiﬁcations in this region with potential regu-
latory functions. Previous studies have shown that TDG
is phosphorylated in living cells (24) and in silico analysis
identiﬁed several putative protein kinase C (PKC) a/b/g
phosphorylation sites in the amino-terminal lysine-rich
regulatory domain. PKC comprises a family of 11
related signalling proteins with diﬀerent tissue distribu-
tions and cofactor requirements that participate in
diverse cellular processes such as proliferation, apoptosis
and diﬀerentiation (25). PKC signalling is activated by
oxidative stress (26), and there is evidence that Polb and
mismatch repair proteins Msh2 and Msh6 are regulated by
PKC phosphorylation (27,28). In this study, we identify a
novel mechanism of crosstalk between CBP and PKCa
that regulates the DNA mispair-processing functions of
TDG through mutually exclusive covalent modiﬁcation
of the amino-terminal region. We demonstrate that
acetylation of lysine residues not directly involved in
DNA binding, selectively and potently abrogates G:T pro-
cessing, whereas phosphorylation of adjacent serine
residues by PKCa may preserve this function by prevent-
ing CBP-mediated acetylation. These ﬁndings highlight
the importance of covalent modiﬁcations in regulating a
DNA repair enzyme integral to the maintenance of CpG
dinucleotides and epigenetic regulation.
MATERIALS AND METHODS
Plasmids
pCMX-based mammalian expression vectors for FLAG
epitope-tagged TDG have been previously described
(15). Amino acid substitution mutants of TDG were
constructed using the Quickchange mutagenesis kit
(Stratagene) according to the manufacturer’s directions
and were veriﬁed by sequencing. A retroviral TDG
expression vector was generated using the pLNCX
vector (Clontech). Other expression vectors have been
previously described (15,20,29).
Antibodies and peptides
TDG-speciﬁc rabbit polyclonal antibody has been
previously described (20). Human PKCa-speciﬁc
polyclonal antibodies (sc-208 or sc-208-G) were obtained
from Santa Cruz Biotechnology. Antipolyhistidine (HS1)
and anti-FLAG monoclonal antibodies (M2) were
obtained from Sigma-Aldrich. TDG peptides obtained
from GenScript Corporation were analysed by mass
spectrometry and quantiﬁed by reverse phase HPLC.
Cell culture and metabolic labelling
NIH3T3 ﬁbroblasts were maintained in Dulbecco’s
minimal essential medium (D-MEM) containing penicil-
lin/streptomycin and supplemented with 10% fetal calf
serum. For subcellular localization experiments, cells
were grown under serum-free conditions for 4h and then
treated with either 100nM phorbol 12-myristate 13-acetate
(PMA) or vehicle [dimethyl sulphoxide (DMSO)] for
15min in serum-containing media. For metabolic-labelling
experiments, 150mm dishes of NIH3T3 or HEK 293T cells
were transfected with TDG expression vectors using the
Polyfect transfection reagent (Qiagen). Approximately
24h later, the culture medium was replaced with serum
and phosphate-free D-MEM, and the cells were incubated
at 37C for 2h. Subsequently,
32P-orthophosphate
(200mCi/ml) was added to the media followed by a 2.5-h
incubation at 37C, which included treatment with PMA
or vehicle (DMSO) during the ﬁnal 30min. Cells were then
washed with phosphate-buﬀered saline (PBS), and
whole-cell extracts were prepared for immunopreci-
pitations as described below. Immunoprecipitates were
separated by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS–PAGE) and incorporation of
32P
was detected by phosphorimaging. Equal loading of
TDG was veriﬁed by immunoblotting.
Preparation of whole-cell extracts and
immunoprecipitations
Whole-cell extracts for immunoprecipitation were
prepared from 100-mm dishes of NIH3T3 cells stably
expressing FLAG–TDG and control cells transduced
with the empty expression vector (pLNCX). Cells grown
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pelleted by centrifugation and resuspended in 500mlo f
Lysis buﬀer [50mM Tris–HCl pH 7.9, 300mM NaCl,
1mM EDTA, 1mM EGTA 10% glycerol, 0.5% Triton
X-100, 1mM dithiothreitol (DTT), 50mM sodium
ﬂuoride, 200mM sodium orthovanadate and proteinase
inhibitors—20mg/ml pepstatin A, 10mg/ml aprotinin,
1mg/ml leupeptin, 0.5mM PMSF] and incubated on ice
for 30min. Subsequently, the cell lysate was diluted with
500ml of dilution buﬀer (50mM Tris–HCl pH 7.9, 1mM
EDTA, 1mM EGTA, 10% glycerol, 1mM DTT, 50mM
sodium ﬂuoride, 200mM sodium orthovanadate and
proteinase inhibitors) and insoluble material removed by
centrifugation. Whole-cell extracts were precleared twice
with 50ml (50% v/v) rabbit IgG-agarose (Sigma-
Aldrich) for 30min at 4C and immunoprecipitated with
50ml (50% v/v) anti-FLAG aﬃnity resin (M2 agarose,
Sigma-Aldrich). Immunoprecipitated proteins were sepa-
rated by SDS–PAGE and detected by immunoblotting.
In the case of immunoprecipitations of radiolabelled in
vivo phosphorylated TDG (pTDG), detection following
SDS–PAGE was carried out by phosphorimaging and
equal loading of TDG was veriﬁed by immunoblotting.
2D PAGE
Cell lysates and (two-dimensional) 2D PAGE analysis
were performed as previously described (30). Cells were
grown to 80–90% conﬂuency in 150-mm dishes and
treated with PMA as described above. Approximately
150mg of cell lysate was fractionated by isoelectric
focusing using a 7-cm Immobiline DryStrip gel (pH 6.2–
7.5; Amersham/Pharmacia). Subsequently, proteins on the
Immobiline Dry strip were fractionated by SDS–PAGE,
and TDG was detected by immunoblotting.
Protein puriﬁcation and in vitro interaction assays
Protein puriﬁcation, GST-based interaction assays,
nickel-based pull-downs and immunoprecipitation proce-
dures have been previously described (15,20).
Base excision and electrophoretic mobility shift assays
Base-excision assays and electrophoretic mobility shift
assays (EMSA) were performed as previously described
using identical oligonucleotide substrates (20). Either
25 or 12ng of recombinant TDG was incubated at 30C
with 10ng of radiolabelled duplex oligonucleotide (25 base
pairs) containing a single G:U or G:T mispair in 20mlo f
buﬀer (25mM HEPES–KOH [pH 7.8], 1mM EDTA,
0.1mg/ml BSA and 1mM DTT). Reactions were carried
out for 30min followed by the addition of 2.5ml 50%
glycerol, and 10ml of the reaction was used directly for
EMSA. EMSA samples were fractionated using 6%
polyacrylamide gels cast in 0.25TBE and pre-run for
1.5h in 0.5TBE. Protein–DNA complexes were
detected by autoradiography or phosphorimaging. The
remainder of the reaction was treated with alkali to
cleave the abasic sites generated by base release, and
subsequently the samples were analysed by denaturing
polyacrylamide electrophoresis as described by
Hardeland et al. (2002).
Avidin–biotin coupled DNA-binding assays
The avidin–biotin coupled DNA-binding (ABCD) assay
was performed as described in ref. 15 using identical
biotinylated duplex oligonucleotides. Brieﬂy,
streptavidin-coated paramagnetic beads (MagneSphere,
Promega) were prepared by washing 0.6ml (1mg/ml)
with ABCD assay buﬀer [50mM Tris–HCl (pH 7.9),
150mM NaCl, 10% glycerol, 5mM MgCl2, 0.1% NP40
and 0.5mM DTT] and resuspending in a ﬁnal volume of
200ml. Approximately 250–500ng of annealed
oligonucleotide was incubated for 30min at room temper-
ature with 10ml of the streptavidin-coated paramagnetic
bead slurry and 100–500ng of puriﬁed bacterially
expressed TDG in a total volume of 50ml of ABCD
buﬀer. Following incubation, beads were washed ﬁve
times with 200ml of ABCD buﬀer, and bound proteins
were recovered by resuspending in 12ml Laemmli buﬀer
and incubation at 90C for 5min. Proteins were
fractionated by SDS–PAGE and detected by
immunoblotting with an antipolyhistidine antibody. In
experiments addressing the displacement of TDG from
abasic sites, we ﬁrst incubated TDG with DNA at room
temperature for 10min, and subsequently GST–APE was
added with further 30-min incubation.
Preparation of acetylated and phosphorylated TDG
for biochemical studies
Acetylated TDG (acTDG) was prepared by incubating
recombinant TDG (750ng) with 1mg recombinant CBP
and 1.25mM acetyl coenzyme A (AcCoA) in acetylation
buﬀer (20mM HEPES [pH 7.8], 1mM EDTA, 1mM
DTT, 10mM sodium butyrate and 10% glycerol) at
30C for 90min. Subsequently, acetylation reactions
were dialysed for 60min against Nickel-binding buﬀer
(NiBB) (50mM Tris–HCl [pH. 8.0], 100mM NaCl, 5%
glycerol, 0.1% NP40, supplemented with 200mM sodium
orthovanadate, 50mM sodium ﬂuoride and 10mM
sodium butyrate). NiBB (500ml) and 60ml (50% v/v)
Ni–NTA agarose were then added to the dialysed reac-
tions, and they were incubated at 4C for 90min. The Ni–
NTA agarose was then washed three times with 200ml
NiBB, and TDG was eluted three times with 50mlo f
NiBB containing 1M imidazole. Eluted TDG was then
dialysed against NETN (50mM Tris [pH 8.0], 100mM
NaCl, 1mM EDTA, 0.1% NP-40, 10% glycerol and
1mM DTT) for 60min. The ﬁnal concentration of TDG
was determined by immunoblotting. Phosphorylated
TDG (pTDG) was prepared by incubating recombinant
TDG (750ng) with 50mU recombinant PKCa
(Calbiochem) and 1mM ATP in 50ml PKC
phosphorylation buﬀer (20mM HEPES, pH 7.2, 1mM
sodium orthovanadate, 25mM glycerol-3-phosphate,
1mM DTT, 1mM CaCl2, 15mM MgCl2, 10mg/ml
1,2-dioleyl-sn-glycerol and 100mg/ml phosphatidylserine)
for 90min at 30C. Mock reactions were performed in the
absence of ATP. Subsequently, TDG was puriﬁed as
described above.
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Puriﬁed phosphorylated or mock-pTDG (100ng) was
incubated with 100ng of puriﬁed, recombinant CBP in
30ml of acetylation buﬀer in the presence of 1.5mM
14C
acetyl AcCoA and incubated for 30min at 30C prior to
stopping of the reaction by addition of 30ml of Laemmli
buﬀer and incubation at 95C for 5min. Reaction compo-
nents were then separated by SDS–PAGE. After separa-
tion, the gel was ﬁxed in a 30% methanol, 10% acetic acid
solution and treated with amplifying solution (Amersham)
prior to imaging by autoradiography or phosphorimaging.
Mock-acetylated or acTDG were incubated with 0.25mU
of recombinant PKCa in phosphorylation buﬀer with 1ml
g
32P-ATP. Reactions were incubated at 30C for 30min
and then stopped by addition of Laemmli buﬀer and
heated at 95C for 5min. Reaction products were then
separated by SDS–PAGE. The gel was ﬁxed with a 30%
methanol and 10% acetic acid solution, and
32P incorpo-
ration was detected by autoradiography. To examine the
eﬀect of DNA on acetylation or phosphorylation, we
preincubated TDG with DNA for 30min on ice before
proceeding with the reaction.
Immunostaining and microscopy
NIH3T3 cells were ﬁxed for 15min with 4% formaldehyde
in PBS followed by a 10-min incubation with 0.1M
glycine in PBS. Cells were then permeabilized with 0.5%
Triton X-100 in PBS for 10min. Immunostaining was per-
formed with the appropriate primary antibodies and
ﬂuorophore-conjugated Donkey secondary antibodies
(CY3, FITC) (Jackson ImmunoResearch Laboratories).
Epiﬂuorescence imaging was performed on an Axiovert
200M inverted microscope equipped with an Apotome
(Carl Zeiss) using appropriate ﬂuorophore-speciﬁc ﬁlter
sets. Z-series images (63magniﬁcation) were acquired
at 0.5-mm intervals and processed with Axiovision
software and Adobe Photoshop. Fluorescence intensity
plots were obtained by performing a line scan bisecting
the cell using Axiovision software.
RESULTS
Phorbol ester-stimulated phosphorylation of TDG
in living cells
We have previously shown that TDG is acetylated by
CBP/p300 at four lysine residues located within an
amino-terminal region essential for DNA binding and
G:T processing (Figure 1A) (15,20,21). In silico analysis,
using the Scansite algorithm (31), revealed several poten-
tial PKC a/b/g phosphoacceptor residues ﬂanking
acetyl-acceptor lysines, suggesting possible functional
interplay between PKC and CBP/p300 signalling in
TDG regulation. These residues are located within a
short sequence motif (
93SKKSGKS
99) that is conserved
Figure 1. Phorbol ester-stimulated phosphorylation of TDG in living cells. (A) Illustration of the functional domains of mouse TDG and sites of
posttranslational modiﬁcation. The central-conserved glycosylase domain is suﬃcient for processing of G:U mispairs while a more divergent
amino-terminal extension is required for tight DNA binding and G:T processing (20,21). Two SUMO-binding motifs (SBM1 and SBM2) and the
sumoylation site (K341) are shown. A lysine-rich regulatory region located in the amino-terminus is acetylated by CBP/p300 at four distinct lysines
(K70, K94, K95 and K98) (15). Putative protein kinase C (PKC) a/b/g-phosphorylation sites (consensus [S/T-X-[R/K]) within a sequence (boxed)
conserved in mouse, rat and human TDG are indicated by asterisks. Complete sequence alignments and accession numbers are found in Figure S1.
(B) 2D PAGE analysis of cellular TDG demonstrates PMA-dependent alterations in apparent molecular weight and isoelectric point (pI). Cell lysates
were prepared from NIH3T3 cells stimulated with PMA and then separated by 2D PAGE. TDG was detected by immunoblotting with a
TDG-speciﬁc antibody. (B) In vivo metabolic labelling of transiently expressed TDG with
32P-orthophosphate. Transfected NIH3T3 ﬁbroblasts
were grown in serum-free media and metabolically labelled with or without PMA treatment. One population of transfected cells was pretreated with
a PKCa/b inhibitor (Go ¨ 6976) before PMA stimulation. Immunoprecipitated TDG was fractionated by SDS–PAGE and analysed by
phosphorimaging (upper panel) and immunoblotting (lower panel).
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whether endogenous TDG is phosphorylated in living cells
in response to treatment with PKC agonist PMA;
serum-starved NIH3T3 mouse ﬁbroblasts were treated
for 15min, and whole-cell lysates were subjected to
2D PAGE. Fractionated cellular proteins were
immunoblotted with TDG-speciﬁc antibodies.
Theoretically, each phosphorylation event leads to a 78
Da gain in molecular weight and a 0.11–0.14 decrease in
isoelectric point. We observed increases in apparent
molecular weight and discrete changes in isoelectric
point in response to PMA treatment consistent with
phosphorylation of TDG in vivo (Figure 1B). We next
veriﬁed that TDG is phosphorylated in living cells by met-
abolic labelling of NIH3T3 cells transiently transfected
with FLAG epitope-tagged TDG. Cells grown under
serum-free conditions were labelled with
32P inorganic
phosphate for 2.5h, which included a 30-min treatment
with either PMA or DMSO. TDG was immunopre-
cipitated from cell lysates with anti-FLAG resin and
quantiﬁed by immunoblotting. Subsequently, comparable
levels of TDG were analysed by SDS–PAGE, and
incorporation of
32P was detected by phosphorimaging.
We observed a basal level of phosphorylation that was
enhanced by PMA treatment (Figure 1C, top panel).
Pretreatment of cells with a PKCa/b-speciﬁc inhibitor
(Go ¨ 6976) (32) prior to PMA stimulation abolished
phosphorylation. Since the ubiquitous expression of
PKCa (33) is more consistent with the wide tissue distri-
bution of TDG, we focused our investigations on this
isozyme. To obtain corroborating evidence for a link
between PKCa and TDG, we examined the subcellular
distribution of the endogenous proteins in NIH3T3
ﬁbroblasts and undiﬀerentiated P19 embryonal carcinoma
cells by indirect immunoﬂuorescence. In NIH3T3 cells
cultured in the absence of serum, PKCa displayed
predominantly cytoplasmic distribution while TDG was
found almost exclusively in the nucleus (Figure 2A,
panels I, III and V). Treatment with PMA for 15min in
the presence of serum, triggered nuclear translocation of
PKCa as previously reported (34) and colocalization with
TDG (Figure 2C, panels II, IV and VI). We observed
mainly nuclear staining for PKCa (35) in untreated P19
cells and strong colocalization with TDG (Figure 2B).
Figure 2. Subcellular localization of TDG and PKCa in NIH3T3 ﬁbroblast and P19 EC cells. (A) Subcellular localization of endogenous TDG and
PKCa in NIH3T3 cells. Serum-starved cells were treated with PMA or DMSO and subsequently immunostained for TDG and PKCa.( B)
Undiﬀerentiated P19 embryonic carcinoma cells (not treated) were immunostained to detect endogenous TDG and PKCa. Representative optical
sections generated by epiﬂuorescence microscopy are shown. The ﬂuorescence intensity plot illustrates the coincidence of peak ﬂuorescence for TDG
(CY3, red) and PKCa (FITC, green).
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demonstrating phosphorylation of nuclear proteins by
PKCa (36).
PKCa interacts directly with TDG and phosphorylates
the amino-terminal region
To determine whether TDG and PKCa associate in living
cells, we carried out immunoprecipitations with
anti-FLAG aﬃnity resin on cell lysates derived from
PMA-treated NIH3T3 ﬁbroblasts stably expressing
FLAG-tagged TDG. The amount of full-length
FLAG-tagged TDG in these cells is comparable to that
of endogenous TDG (Figure 3A, compare lanes 1 and 2).
Immunoprecipitates were separated by SDS–PAGE and
immunoblotted for TDG and PKCa. PKCa was only
detected in immunoprecipitates derived from FLAG–
TDG expressing cells but not from control cells, consistent
with the association of these proteins in living cells (Figure
3A, compare lanes 3 and 4). Similar results were obtained
using transiently expressed epitope-tagged proteins
(Figure S2). To examine whether these proteins interact
directly, we carried out in vitro interaction studies using
commercially available recombinant PKCa and
polyhistidine-tagged TDG or a truncated variant lacking
the amino-terminal region (residues 1–121) (Figure 3B).
Following incubation of these proteins, nickel-aﬃnity
resin was used to pull down TDG, and PKCa was
detected by immunoblotting (Figure 3C). PKCa was
retained on the nickel-aﬃnity resin in the presence of
full-length TDG but not with the amino terminal
variant. Coomassie staining of an aliquot of the binding
reaction conﬁrmed that both TDG and TDG(122–421)
were bound to the aﬃnity resin. These ﬁndings establish
a direct interaction between TDG and PKCa that is
dependent on the amino-terminal region of TDG.
We next assessed whether TDG is a direct substrate for
PKCa phosphorylation in vitro, by incubating
recombinant TDG or TDG(122–421) and PKCa in the
presence of g
32P-ATP and essential cofactors;
subsequently, the reaction products were fractionated by
SDS–PAGE, and incorporation of
32P was measured by
phosphorimaging (Figure 4A). Incorporation of radioac-
tivity was observed only with full-length TDG, indicating
that the amino-terminal region is essential for
phosphorylation by PKCa. Considering that PKCa/b/g
consensus phosphorylation sites are located adjacent to
acetyl-acceptor lysines 94, 95 and 98 (see Figure 1A), we
employed two short peptides consisting of amino acid
residues 68–91 and 91–107 in phosphorylation reactions
to further delineate the location of phosphoacceptor
serines or threonines. Analysis of the reaction products
by SDS–PAGE and phosphorimaging revealed that the
peptide containing residues 91–107 was robustly
phosphorylated in vitro while the second peptide
(residues 68–91) was not appreciably radiolabelled
(Figure 4B). Phosphorylated residues were identiﬁed by
examining the eﬀect of alanine substitutions of potential
phosphoacceptor residues in the context of the 91–107
peptide. This analysis indicated that substitution of
serine 96 (S96) and serine 99 (S99) substantially decreased
32P incorporation, thereby identifying these residues as the
principal phosphoacceptor sites (Figure 4C). In the
context of full length bacterially expressed TDG, dual sub-
stitution of these residues with either alanine (S96–99A) or
aspartate (S96–99D) resulted in 60 and 80% reduction in
phosphorylation, respectively (Figure 4D). To assess
whether these serines are phosphorylated in vivo,w e
transiently expressed FLAG-tagged wild-type TDG and
TDG(S96–99D) in NIH3T3 ﬁbroblasts and carried out
metabolic labelling with radiolabelled inorganic phos-
phate with and without PMA stimulation. We observed
that PMA treatment increased phosphorylation of
wild-type TDG by 80% but had no detectable eﬀects
on the S96–99D mutant (Figure 4E, upper panel) conﬁrm-
ing that these are the major phosphoacceptor sites.
Immunoblotting analysis indicated the presence of com-
parable amounts of TDG in the diﬀerent immunopre-
cipitates (Figure 4E, lower panel). These data conﬁrm
that phosphorylation of serine 96 and 99 of TDG is
induced by phorbol ester stimulation in living cells.
Amino-terminal acetylation and phosphorylation
are mutually exclusive
The proximity of the acetylated residues to the PKCa
phosphorylation sites (see Figure 1A) suggested that
Figure 3. PKCa associates directly with TDG. (A) PKCa
coimmunoprecipitates with stably expressed TDG in NIH3T3
ﬁbroblasts. Immunoprecipitations using anti-FLAG aﬃnity resin were
carried out on whole-cell extracts prepared from PMA-treated cells
stably expressing FLAG–TDG or control cells transduced with the
empty expression vector. Aliquots of the cell lysates and immunopre-
cipitated proteins were immunoblotted for PKCa and TDG.
(B) Coomassie staining of polyhistidine-tagged TDG and TDG(122–
421) used for in vitro protein interaction studies. (C) In vitro association
of recombinant TDG and PKCa requires amino-terminal residues 1–
121 of TDG. Approximately 1mg polyhistidine-tagged TDG or
TDG(121–421) were incubated with 10ng of PKCa and subjected to
pull down with nickel-aﬃnity resin. As a control, PKCa was also
incubated with beads alone. Bound proteins were subjected to SDS–
PAGE and immunoblotting with a PKCa-speciﬁc antibody (upper
panel). Binding of poly-histidine-tagged TDG and TDG(122–421) to
the nickel-aﬃnity beads was conﬁrmed by Coomassie staining (lower
panel).
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eﬀective charge in this region. To investigate this, we
established an assay whereby we initially acetylated or
phosphorylated recombinant TDG in vitro and then
used nickel-aﬃnity chromatography to purify TDG from
the modifying enzymes. Following quantiﬁcation by
immunoblotting, we assessed whether acTDG could be
phosphorylated by PKCa and vice versa. We found that
acTDG was not appreciably phosphorylated by PKCa
(Figure 5A) and similarly, when pTDG was used as a
substrate for CBP, acetylation was greatly reduced
(Figure 5B). Quantiﬁcation by phosphorimaging
revealed a 10-fold and 3-fold reduction in
phosphorylation and acetylation, respectively. The more
moderate decrease in acetylation, following
phosphorylation, is consistent with the presence of an
additional acetyl-acceptor lysine (K70), which may not
be aﬀected by phosphorylation. To determine whether
loss of positive charges at acetyl-acceptor lysines was
responsible for inhibition of phosphorylation, we
introduced charge neutralizing alanine substitutions at
lysines 94, 95 and 98 (K94-95-98A triple mutant), which
constitute the major acetylation sites in vitro and carried
out in vitro phosphorylation (Figure 5C). Reduced levels
Figure 4. PKCa phosphorylates TDG on serines 96 and 99. (A) PKCa-mediated phosphorylation of TDG requires the amino-terminal region. In
vitro phosphorylation reactions were performed in the presence of g
32P-ATP using 2mg of TDG (lane 1) or TDG(122–421) (lane 2) and 0.3ng of
recombinant PKCa. Reaction products were fractionated by SDS–PAGE and incorporation of
32P was detected by phosphorimaging. (B)
Delineation of the phosphorylated region using peptide probes. Equimolar amounts of TDG peptides (residues 68–91 and 91–107) and PKCa
peptide substrate from glycogen synthetase (residues 1–8 and designated GS 1–8) along with the FLAG peptide were reacted with PKCa and
analysed as indicated earlier. (C) Identiﬁcation of phosphoacceptor residues by alanine substitution. In vitro phosphorylation of the TDG(91–107)
(1mg) peptide and alanine-substituted derivatives was performed and analysed by SDS–PAGE and phosphorimaging (top panel). Quantiﬁcation of
signal intensity is displayed in the bottom panel. Lysines acetylated by CBP/p300 are indicated with asterisks. (D) Dual alanine (lane 2) or aspartate
(lane 3) substitutions of serine 96 and 99 reduces PKCa-mediated phosphorylation in full-length TDG. Recombinant TDG and the indicated
substitution mutants (2mg) were phosphorylated in vitro and analysed by SDS–PAGE and autoradiography. (E) In vivo metabolic labelling of
transiently expressed TDG and S96-99D mutant with
32P-orthophosphate. Transfected NIH3T3 ﬁbroblasts grown in serum-free media were
metabolically labelled for 2.5h, which includes treatment with either vehicle or PMA during the ﬁnal 30min of labelling. Proteins were immunopre-
cipitated with anti-FLAG resin and then fractionated by SDS–PAGE and phosphorimaged (upper panel). Aliquots of the immunoprecipitates were
analysed by immunobloting to ensure equal loading of TDG (lower panel).
Nucleic Acids Research,2010, Vol.38, No. 4 1141of phosphorylation were observed with the mutant consis-
tent with lysine residues being essential for optimal
phosphorylation by PKCa. Serine to aspartate substitu-
tions (S96 and S99), which mimic phosphorylation, also
reduced acetylation consistent with the mutually exclusive
relationship (Figure 5D). We next examined the relation-
ship between these modiﬁcations in living cells by carrying
out in vivo phosphorylation experiments in HEK 293T
cells. This cell line was chosen due to the high-transfection
eﬃciency that can be routinely achieved and the fact that
TDG acetylation can be readily observed by metabolic
labelling (data not shown). As with NIH3T3 ﬁbroblast,
we observed PMA-dependent phosphorylation of TDG,
which could be attenuated by coexpression of CBP (60%
reduction) (Figure 5E). Furthermore, the TDG mutant
with alanine substitutions at acetyl-acceptor lysines
was not phosphorylated in a PMA-dependent manner.
These ﬁndings are in agreement with the in vitro data
and consistent with a mutually exclusive relationship
between acetylation by CBP/p300 and PKC-mediated
phosphorylation. When we performed in vivo acetylation
by metabolic labelling with
3H sodium acetate, we found
Figure 5. Acetylation and phosphorylation are mutually exclusive. (A) Acetylated TDG (acTDG) is refractory to phosphorylation by PKCa.
Recombinant polyhistidine-tagged TDG was acetylated in vitro with CBP and then puriﬁed by nickel-aﬃnity chromatography. acTDG was
quantiﬁed by immunoblotting and 100ng was used in phosphorylation reactions that included g
32P-ATP. Reaction products were analysed by
SDS–PAGE and phosphorimaging. (B) Phosphorylated TDG (pTDG) is refractory to acetylation by CBP. pTDG was puriﬁed as indicated above
and reacted with CBP and in the presence of
14C-acetyl coenzyme A (AcCoA). (C) Reduced in vitro phosphorylation of the K94-95-98A mutant. (D)
Reduced in vitro acetylation of the S96-99D mutant. Recombinant proteins (1mg) were phosphorylated or acetylated in vitro as described above. (E)
Inhibition of in vivo TDG phosphorylation by coexpression of CBP or substitution of positively charged acetyl-acceptor lysines. HEK 293T cells were
transfected with the indicated expression vector and metabolically labelled with and without stimulation with PMA.
1142 Nucleic Acids Research, 2010,Vol.38, No. 4surprisingly that both the S96-99D mutant and wild-type
TDG were acetylated at comparable levels (data not
shown). These ﬁndings are consistent with our
unpublished data, indicating that TDG is acetylated by
other acetylases in addition to CBP/p300.
Divergent eﬀects of TDG acetylation and phosphorylation
on DNA mispair processing
DNA binding has been reported to promote
conformational changes in TDG (21). To address
whether TDG could be acetylated or phosphorylated
when bound to DNA, we carried out acetylation reactions
with CBP in the presence of increasing amounts of either
normally paired or G:T mispaired duplex oligonucleotides
(Figure 6A). A considerable reduction in acetylation of
TDG was observed in the presence of either oligonu-
cleotide, while CBP autoacetylation was not signiﬁcantly
aﬀected. These ﬁndings suggest that in vivo TDG bound to
DNA is unlikely to be acetylated by CBP/p300. In
contrast, the presence of DNA had little eﬀect on the
acetylation of GST-p53 and SET (TAF1b) proteins
(Figure 6B). Additionally, the presence of duplex
oligonucleotides caused a more moderate reduction in
PKCa-mediated phosphorylation (Figure 6C), suggesting
that phosphorylation of TDG may occur on DNA.
The marked reduction in acetylation following DNA
binding suggests that the acetyl-acceptor lysines may
directly contact DNA. To investigate this possibility, we
compared the DNA-binding activity of bacterially
expressed recombinant wild-type TDG and the
K94-95-98A mutant using the EMSA (37). We found
that the alanine-substitution mutant displayed moderately
enhanced binding to duplex oligonucleotides containing
either G:U or G:T mispairs (Figure 6D). Interestingly,
we found that the mutant bound to an abasic site was
resistant to displacement by APE compared to wild-type
TDG (Figure S3). These ﬁndings suggest that lysines
94, 95 and 98 are critical determinants of the DNA-
binding properties of TDG and that these positively
charged residues are not directly interacting with DNA
but may be conformationally important.
Figure 6. DNA binding prevents CBP-mediated acetylation of TDG. (A) Dose-dependent inhibition of TDG acetylation by duplex oligonucleotides.
TDG (150ng) was preincubated with the indicated duplex oligonucleotides for 30min on ice and then acetylated in vitro with CBP (100ng) and
14C-AcCoA. Reaction products were analysed by SDS–PAGE and autoradiography. (B) DNA-dependent inhibition of CBP-mediated acetylation is
speciﬁc to TDG. In vitro acetylation was performed with TDG (150ng), GST-p53 (150ng) and SET/TAF-1b (150ng) recombinant proteins in the
presence or absence of 200ng of G:T mispaired oligonucleotide. (C) Phosphorylation of TDG in the presence of duplex oligonucleotides. In vitro
phosphorylation reactions were performed as described in Figure 4 using TDG preincubated with 200ng of the indicated oligonucleotides. (D)
Alanine substitution of acetyl acceptor lysines enhances DNA binding. Electrophoretic mobility shift assay was carried out with radiolabelled duplex
oligonucleotides bearing either a G:U or a G:T mispair with 25ng of recombinant wild-type TDG or TDG(K94-95-98A).
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of TDG in G:T processing and the observed inhibition of
CBP-mediated acetylation by DNA, we investigated
whether acetylation or phosphorylation could modulate
DNA interactions. To address this, we produced puriﬁed
covalently modiﬁed (acetylated or phosphorylated)
recombinant TDG in vitro using nickel-aﬃnity chroma-
tography (see Figure 5). As controls, we also carried out
mock acetylation and phosphorylation reactions using
heat-denatured CBP or by omission of ATP, respectively.
We assayed in vitro modiﬁed TDG for DNA-binding and
G:T/U processing activity using asymmetrically
radiolabelled duplex oligonucleotides containing the
indicated DNA mispairs. Remarkably, we observed that
acTDG retained robust G:U processing activity but dis-
played severely reduced G:T processing (Figure 7A,
compare lane 4 and 6). Consistent with these ﬁndings,
we observed using both the ABCD-binding assay (data
not shown) and EMSA (Figure 7B) that the binding
of acTDG to G:U-mispaired oligonucleotides was
comparable to that of mock acTDG, whereas binding to
G:T mispaired DNA was substantially reduced.
Therefore, these data indicate that acetylation of the
amino-terminal region selectively abrogates the G:T
processing functions of TDG. In contrast, the DNA
binding and mispair-processing activities of pTDG were
generally indistinguishable from mock phosphorylated
protein (Figure 7C and D). To conﬁrm that we achieved
eﬃcient phosphorylation of TDG in this experiment, we
carried out an acetylation reaction with this material and
observed a threefold reduction in incorporation of
radiolabelled AcCoA (data not shown). Therefore,
although PKCa-mediated phosphorylation does not
appear to directly alter the processing functions of TDG
it may prevent inhibition of G:T processing by preventing
acetylation by CBP/p300.
DISCUSSION
We have elucidated a unique interplay between acetylation
and phosphorylation in regulating the DNA-repair func-
tions of TDG. We show that these posttranslational mod-
iﬁcations occur on adjacent residues in the
amino-terminus and are mutually exclusive. Remarkably,
acetylation by CBP/p300 selectively abrogates G:T pro-
cessing while phosphorylation by PKCa may preserve
this function in vivo by preventing CBP-mediated
acetylation. Our ﬁndings suggest that the opposing regu-
latory roles of CBP/p300 and PKC may have profound
eﬀects on the functions of TDG in CpG maintenance and
epigenetic regulation.
Figure 7. Divergent eﬀects of acetylation and phosphorylation on DNA mispair processing. (A) Acetylation of TDG selectively abrogates G:T
processing. Puriﬁed acetylated TDG (acTDG) (25ng) was prepared as described in Figure 5, and base-excision assays were carried out using
asymmetrically radiolabelled duplex oligonucleotides (10ng) bearing either G:U or G:T mispairs. Reaction products were treated with alkali to
cleave the abasic sites and analysed by denaturing PAGE and autoradiography. (B) acTDG does not stably bind oligonucleotides bearing a G:T
mispair. Aliquots of base-excision reactions described above were subjected to electrophoretic mobility-shift assays to determine binding to G:U or
G:T mispaired oligonucleotides. (C) Phosphorylation of TDG does not detectably alter G:T/U processing activity. Phosphorylated (pTDG) and
mock pTDG (12ng) were tested for ability to excise mispaired uracil and thymine. (D) DNA-binding analysis of phosphorylated and mock pTDG.
Aliquots of the base-excision reactions were subjected to electrophoretic mobility-shift analysis. Supplementary Figures S4 and S5 show images of
EMSA gels that include unbound DNA probe.
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TDG-mediated base excision on the basis of the proximity
of putative PKCa/b/g phosphorylation sites and
acetyl-acceptor lysines (K94, K95 and K98). These
residues are located within a sequence motif conserved
in mouse, rat and human TDG (
93SKKSGKS
99).
Our studies indicate that, in mouse ﬁbroblasts, PKCa
translocates to the nucleus in response to PMA stimulation
and phosphorylates residues in the amino-terminal
DNA-binding domain of TDG. Accordingly, we
have shown that in NIH3T3 cells, stably expressed
TDG coimmunoprecipitates with endogenous PKCa.
Furthermore, 2D PAGE analysis and metabolic labelling
indicate that TDG is phosphorylated in a PMA-dependent
manner in vivo, and this eﬀect was abrogated by a PKCa/b
inhibitor. Using recombinant bacterially expressed
proteins, we have shown that PKCa interacts directly
with TDG, and this association requires the amino-
terminal region of TDG (residues 1–122). The
phosphorylation sites were mapped in vitro using
peptides bearing alanine substitutions of potential
phosphoacceptor residues. We identiﬁed two serine
residues (S96 and S99) that when mutated in the context
of full-length TDG, substantially reduced phosphorylation
by PKCa. Consistent with this, in vivo PMA-dependent
phosphorylation of transiently expressed TDG was sub-
stantially reduced when the phosphoacceptor serines
were substituted with aspartate. Although we have
focused on PKCa in our studies, these phosphoacceptor
serines maybe phosphorylated byother PKC subtypes.We
have used PMA to induce nuclear translocation of PKCa;
however, it is well known that in ﬁbroblasts this is a normal
physiological response to growth factor (e.g., PDGF and
EGF) stimulation (38). Therefore, phosphorylation of
TDG may be regulated by mitogenic signals.
Interestingly, in undiﬀerentiated P19 EC cells, PKCa is
mostly nuclear and colocalizes with TDG, consistent
with a role in the regulation of nuclear processes.
Considering the proximity of phosphoacceptor serines
and acetyl-acceptor lysines and the diﬀerent charge char-
acteristics of these residues upon covalent modiﬁcation, it
should perhaps not be surprising that acetylation
eﬀectively prevents phosphorylation and vice versa. We
found that acetylation of recombinant TDG decreases
subsequent phosphorylation by 10-fold while phospho-
rylation decreases acetylation by at least threefold.
Furthermore, substitution of phosphoacceptor serines
with aspartate, which mimics phosphorylation, reduced
acetylation in vitro while replacement of positively
charged lysines with alanine-reduced phosphorylation.
Consistent with in vitro studies, PMA-induced phospho-
rylation in vivo was abrogated by the removal of acetyl-
acceptor lysines and reduced by CBP overexpression.
Surprisingly, the phosphorylation mimic (S96–99D) was
acetylated in vivo at similar levels to wild-type TDG.
This is most likely attributable to acetylation of TDG in
vivo at other lysine residues by other acetylases. The
mutually exclusive nature of these adjacent modiﬁcations
is reminiscent of the cross-talk observed on the
amino-terminal KS dipeptide of histone H3; in this case,
phosphorylation of S10 blocks both K9 acetylation and
methylation while K9 dimethylation antagonizes S10
phosphorylation (39–42). Similar cross-talk has been sug-
gested for nonhistone proteins (43,44).
In exploring the functional signiﬁcance of these covalent
modiﬁcations, we ﬁrst established whether they could
occur when TDG is bound to DNA as conformational
changes in this context have been reported (19). We
found that DNA-bound TDG was very resistant to
acetylation while CBP autoacetylation was not altered.
In contrast, phosphorylation by PKCa was much less
aﬀected by the presence of DNA. These ﬁndings suggest
that in vivo PKCa may phosphorylate DNA-bound TDG
while acetylation by CBP/p300 requires uncoupling from
DNA. The observation that CBP/p300-mediated
acetylation abrogates binding to duplex DNA and G:T
processing may be relevant to both the CpG maintenance
functions of TDG as well as its recently postulated role in
gene-speciﬁc CpG demethylation (45). acTDG retains the
ability to process G:U mispairs in vitro, consistent with
previous reports indicating that this function does not
require the amino-terminal region (20,21). However, the
reduced ability of acTDG to bind DNA may interfere with
the genome scanning functions attributed to DNA
glycosylases, which could severely hinder detection of
DNA mispairs and other DNA lesions in vivo. G:U and
G:T mispairs at CpG dinucleotides are generated by
hydrolytic deamination of cytosine and methyl cytosine,
respectively. To restore cytosine methylation following
repair of G:T mispairs, a mechanism is required to
discern between mispairs arising from either the
methylated or unmethylated cytosine. CBP/
p300-mediated acetylation may provide a mechanism to
discriminate between the two deamination products.
Recent studies employing chromatin immunoprecipitation
assays have shown that TDG transiently occupies the pro-
moters of several estrogen responsive genes (11,17), and it
has been postulated that TDG and other BER enzymes
are essential for the cyclical CpG demethylation patterns
observed on these genes during transcription. As the
DNA-binding activity and G:T processing functions of
TDG are dramatically reduced by CBP-mediated
acetylation, this may serve as a powerful mechanism to
regulate CpG demethylation and/or the release of TDG
from promoters. The ﬁnding that CBP/p300-mediated
acetylation of Polb reduces end-trimming activity and
impairs participation in BER (22) suggests that CBP/
p300 may generally act as negative regulator of BER.
This is also in agreement with the role of acetylation in
reducing the nuclease activity of another BER enzyme,
ﬂap endonuclease 1 (Fen1) (23). A recent study provided
evidence for the direct excision of 5-methylcytosine by
MBD4, and this activity is stimulated by PKC
phosphorylation (46). Therefore, PKC signalling likely
plays a central role in regulating CpG demethylation by
MBD4 and TDG.
CBP/p300 as well as other protein acetylases respond to
DNA damage and other cellular stresses by acetylating
cellular proteins such as tumor suppressor p53 (47–49).
Covalent modiﬁcation of key-cellular regulatory proteins
is an integral signalling mechanism in DNA damage
response that leads to cycle arrest, apoptosis and cellular
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repair as part of an apoptotic response to cellular stresses
such as excessive DNA damage. In this context, it is inter-
esting to note that both phosphorylation by PKC and
acetylation by p300 has been shown to inactivate Polb,
while, in this study, we demonstrate that phosphorylation
of TDG by PKCa may preserve G:T processing by pre-
venting acetylation by CBP/p300. Altogether, these
ﬁndings suggest that the crosstalk between diﬀerent sig-
nalling pathways could provide exquisite regulation of the
diﬀerent steps of BER in response to physiologic signals or
stresses. Although, in this study, we have focused on the
classic functions of TDG in processing G:T/U mispairs, it
also processes other damaged bases and may be important
in cellular responses to oxidative stress. Along these lines,
since PKC isoenzymes are activated by reactive oxygen
species (50,51), TDG may be a crucial downstream
target that would also be subject to opposing regulation
by CBP/p300.
The tight binding of TDG to abasic sites produced by
base excision prevents enzyme turnover and limits pro-
cessing eﬃciency (21). It has been postulated that
sumoylation of mammalian TDG serves to promote
release of the enzyme from abasic sites (19). Structural
analysis of an amino- and carboxy-terminal deleted
human TDG conjugated to SUMO revealed the
presence of a protruding helix that interferes with DNA
binding (52). However, analysis of sumoylated full-length
human TDG by limited proteolysis suggested that
sumoylation promotes conformational changes involving
interaction of the carboxy- and amino-terminal regions
(21). We have shown previously that mouse TDG
contains two separate conserved amino-terminal and
carboxy-terminal SUMO-binding motifs that interact
intramolecularly with the conjugated SUMO and may
account for the sumoylation-induced conformational
changes (20). Interestingly, both sumoylation and
acetylation by CBP/p300 abrogate DNA binding and pro-
cessing of G:T mispairs (see Figure 8). However, in
contrast to sumoylation, which can occur on DNA, we
show that CBP-mediated acetylation requires the
uncoupling of TDG from DNA. Furthermore, acTDG
retains the ability to form stable complexes with abasic
sites as evidenced by the stable binding observed following
the processing of G:U mispairs. It is plausible that
acetylation promotes limited conformational changes
within the amino-terminus in contrast to the more exten-
sive changes that are associated with sumoylation.
Interestingly, substitution of lysines 94, 95 and 98 with
alanines did not mimic the eﬀects of acetylation on
DNA binding, and this mutant was resistant to displace-
ment by APE when bound to abasic sites (Figure S3).
These ﬁndings suggest that these lysine residues play
critical roles in DNA binding and mispair processing,
and the eﬀects of acetylation are not strictly due to loss
of positive charges.
We have provided biochemical evidence for the inter-
play of CBP/p300 and PKCa in modulating the
DNA-repair functions of TDG. Our studies provide
insights into the complex roles of posttranslational mod-
iﬁcations in regulating genome maintenance and
gene-expression pathways. The fact that both CBP/p300
and PKC signalling pathways are deregulated in
oncogenesis (25,53,54) suggest that TDG may be a down-
stream target that may be functionally compromised and
contribute to the genomic instability associated with
cancer. Interestingly, TDG has recently been shown to
eﬃciently excise 5-ﬂuorouracil from DNA and plays a
role in cellular responses to this commonly used
chemotherapeutic agent (55,56). Our studies indicate it
may be possible to alter the DNA damage processing
functions of TDG in vivo by targeting the signalling
pathways that mediate acetylation and phosphorylation
of this enzyme. Future studies will establish the utility of
our ﬁndings in this context and whether TDG is suitable
target for cancer therapy.
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Figure 8. Cross-talk between TDG posttranslational modiﬁcations.
Previous studies have shown that sumoylation of human and mouse
TDG induces a dramatic increase in G:U processing activity by
promoting enzyme turnover (19,20). In contrast, sumoylation (19,20)
or acetylation by CBP (this study) abrogate DNA binding and G:T
processing (19,20). TDG sumoylation also drastically reduces interac-
tions with CBP/p300, thereby preventing eﬃcient acetylation (20). The
present studies reveal that the phosphorylation of serine residues
adjacent to acetyl-acceptor lysines by PKCa prevents acetylation by
CBP and may preserve G:T processing in vivo.
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